344 related articles for article (PubMed ID: 28805471)
1. Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.
Koopmans-Klein G; Van Op den Bosch J; van Megen Y; Prenen H; Huygen F; Mancini I
Curr Med Res Opin; 2017 Dec; 33(12):2217-2227. PubMed ID: 28805471
[TBL] [Abstract][Full Text] [Related]
2. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
[TBL] [Abstract][Full Text] [Related]
3. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
[TBL] [Abstract][Full Text] [Related]
5. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
[TBL] [Abstract][Full Text] [Related]
6. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
[TBL] [Abstract][Full Text] [Related]
7. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
9. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
Morlion B; Clemens KE; Dunlop W
Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
[TBL] [Abstract][Full Text] [Related]
11. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
[TBL] [Abstract][Full Text] [Related]
12. Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence.
Morlion BJ; Mueller-Lissner SA; Vellucci R; Leppert W; Coffin BC; Dickerson SL; O'Brien T
Pain Pract; 2018 Jun; 18(5):647-665. PubMed ID: 28944983
[TBL] [Abstract][Full Text] [Related]
13. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
[TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
[TBL] [Abstract][Full Text] [Related]
17. Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study.
Hesselbarth S; Löwenstein O; Cegla T
Scand J Pain; 2014 Apr; 5(2):75-81. PubMed ID: 29913668
[TBL] [Abstract][Full Text] [Related]
18. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
Clemens KE; Quednau I; Klaschik E
Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
[TBL] [Abstract][Full Text] [Related]
19. Prolonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.
Hesselbarth S; Hermanns K; Oepen P
Expert Opin Pharmacother; 2015 Mar; 16(4):457-64. PubMed ID: 25612469
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA; Mueller-Schwefe GH
Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
